LOGIN  |  REGISTER
Terns Pharmaceuticals

Tactile Medical to Participate in Upcoming Investor Conferences in February and March

February 05, 2024 | Last Trade: US$9.66 0.14 1.47

MINNEAPOLIS, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will participate in the following upcoming investor conferences:

The BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference at the Cliff Lodge in Snowbird, UT.

  • Management will participate in investor meetings on Tuesday, February 13th. There will be no formal presentation to investors.

The Oppenheimer 34th Annual Healthcare MedTech & Services Conference which is being held virtually.

  • Management will participate in a virtual fireside chat at 2:40 p.m. Eastern Time on Tuesday, March 12th.

About Tactile Systems Technology, Inc. (DBA Tactile Medical)

Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home. The company collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.

Chimerix

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page